Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Feuerstein's Biotech-Stock Mailbag
- Glaxo, Regulus Team on MicroRNA R&D
- Wyeth, Elan Halt Alzheimer Drug Trial
- Del.icio.us
- Digg
- StumbleUpon
ImClone shares closed Friday at $46.05 and were indicated around $2 higher in recent trading.
Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.
Regulus could receive up to $144.5 million in future milestones, and also tiered royalties on sales on each of four microRNA targeted therapeutics
Incidence of a skin lesion prompts the suspension of a phase II trial for their experimental vaccine ACC-001.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
